ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Net Income history
Currency unavailable · from the cash flow
No Net Income data reported for this period type.
Net Income vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $328.6M USD | +96.4% | -4.1% | 412.0% | |
| LTM Mar 2026 | $198.37M USD | -1.8% | +18.2% | 4917.6% | |
| LTM Mar 2026 | $183.59M USD | +63.4% | +8.1% | 255.7% | |
| LTM Mar 2026 | $169.77M USD | -437.7% | -59.2% | 529.2% | |
| LTM Mar 2026 | $145.44M USD | — | +20.7% | 15782.6% | |
| LTM Mar 2026 | $78.67M USD | +15.4% | — | 173.5% | |
| FY2025 | $49.5M USD | — | — | 265.9% | |
| LTM Mar 2026 | €45.62M EUR | +51.2% | -14.2% | 339.4% | |
| LTM Mar 2026 | $41.54M USD | +56.8% | +27.7% | — | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | +51.2% | +8.1% | 375.7% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.